{"id":"W4402259280","doi":"10.1200/jco.24.00110","title":"Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; F. Hoffmann-La Roche; Memorial Sloan-Kettering Cancer Center; Pfizer","keywords":"Medicine; Palbociclib; Tolerability; Internal medicine; Letrozole; Fulvestrant; Oncology; Adverse effect; Metastatic breast cancer; Breast cancer; Cancer; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008890909,0.001304013,0.001264201,0.0003834848,0.0003317299,0.001149751,0.0007812958,0.0007792662,0.007269],"category_scores_gemma":[0.000462293,0.0004826832,0.0009810728,0.000357423,0.0006422636,0.0006254716,0.0003510132,0.002494769,0.001426295],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001018387,"about_ca_system_score_gemma":0.001431958,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009585324,"about_ca_topic_score_gemma":0.003083454,"domain_scores_codex":[0.9998232,0.00006006113,0.000009947436,0.00003604924,0.00002199581,0.00004883071],"domain_scores_gemma":[0.999728,0.00003222798,0.00006607601,0.00001769555,0.00001673844,0.0001392774],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8192333,0.02633897,0.003484631,0.001630289,0.001918365,0.0001749096,0.0001474256,0.002209049,0.02342441,0.0006375252,0.008890373,0.1119109],"study_design_scores_gemma":[0.8030234,0.177817,0.006950813,0.0001192106,0.0006872169,0.000362342,0.00006837858,0.001460425,0.002778149,0.0004103129,0.006293622,0.00002916451],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9681389,0.007225404,0.001120413,0.0008530072,0.000447092,0.005442839,0.002939764,0.0003801907,0.01345239],"genre_scores_gemma":[0.9789318,0.003280092,0.001602387,0.001230902,0.0002175904,0.002639555,0.005394483,0.00005462758,0.006648452],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007269,"threshold_uncertainty_score":0.0243172,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1142235611372019,"score_gpt":0.4995596041199905,"score_spread":0.3853360429827886,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}